Compare Harley-Davidson Inc (HOG) vs Moderna, Inc. (MRNA) Price & Performance

Harley-Davidson (HOG) trades at $26.75, down 0.71% on the day, with a bullish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 14.97 and P/S of 0.72, but faces declining revenue and net income margins. Recent news highlights tariff exposure and a data breach, while analyst consensus is a 'Hold' with a $28.50 price target. Cash flow trends are volatile, with 2025 showing a net inflow of $1.35 billion driven by investing activities.

The outlook for HOG is cautious due to fundamental pressures, including falling profitability and revenue, offset by low valuations and a dividend. Key risks include competitive threats and sensitivity to tariffs. Upside potential exists if the 'Back to the Bricks' strategy revives growth, but investors should weigh margin erosion against valuation support.

Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.

Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.